FY2025 · period end Dec '25 · from the 10-K filed Feb 10, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $402.07B |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0000064803-26-000082 | May 14, 2026 | May 18, 2026 | May 18, 2026 20:13 UTC | EDGAR |
| 8-K | 0000064803-26-000051 | May 6, 2026 | May 6, 2026 | May 6, 2026 10:31 UTC | EDGAR |
| 10-Q | 0000064803-26-000052 | Mar 31, 2026 | May 6, 2026 | May 6, 2026 10:33 UTC | EDGAR |
| 8-K | 0000064803-26-000017 | Mar 18, 2026 | Mar 19, 2026 | Mar 19, 2026 20:08 UTC | EDGAR |
| 8-K | 0000064803-26-000009 | Feb 10, 2026 | Feb 10, 2026 | Feb 10, 2026 11:31 UTC | EDGAR |
| 10-K | 0000064803-26-000010 | Dec 31, 2025 | Feb 10, 2026 | Feb 10, 2026 11:36 UTC | EDGAR |
| 8-K | 0000064803-25-000082 | Dec 9, 2025 | Dec 9, 2025 | Dec 9, 2025 11:33 UTC | EDGAR |
| 8-K | 0001193125-25-289805 | Nov 20, 2025 | Nov 20, 2025 | Nov 20, 2025 21:18 UTC | EDGAR |
Direct links to SEC EDGAR. CVS has additional filings available on the SEC site.
Figures a later SEC filing revised from what was first reported. Each diff compares the same XBRL tag across two filings — both linked, so you can check it yourself.
Operating Income (Loss)·Q2 2018
Major restatementwas-$1.6B
Revised up in a 10-K.
Operating Income (Loss)·Q3 2018
Notable restatementwas$2.4B
Revised up in a 10-K.
Net Income (Loss) Attributable to Parent·FY 2022
Notable restatementwas$4.1B
Revised up in a 10-K. Any P/E built on the original was 3.8% too high.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest·FY 2022
Notable restatementwas$5.6B
Revised up in a 10-K.
Operating Income (Loss)·FY 2022
Notable restatementwas$7.7B
Revised up in a 10-K.
Net Income (Loss) Available to Common Stockholders, Basic·Q2 2022
Notable restatementwas$3B
Revised up in a 10-Q.
CVS is not the only one.
See every restatement we've found across the market — or get an alert the next time CVS revises a number.
Restatements are detected by comparing every vintage of a fact across all of CVS HEALTH Corp's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows CVS's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling CVS HEALTH Corp — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on CVS yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on CVS and publish the result to your public profile.
Get 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs| $357.78B |
| $322.47B |
| $292.11B |
| Gross Profit | $180.90B | $166.52B | $140.68B | $125.58B | $116.31B |
|---|
| Operating Income | $4.66B | $8.52B | $13.74B | $7.95B | $13.31B |
|---|
| Net Income | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B |
|---|
| EPS (Diluted) | $1.39 | $3.66 | $6.47 | $3.26 | $6.02 |
|---|
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $253.54B | $253.22B | $249.73B | $228.28B | $233.05B |
| Total Liabilities | $178.16B | $177.49B | $173.09B | $156.51B | $158.21B |
| Stockholders' Equity | $75.38B | $75.73B | $76.64B | $71.77B | $74.84B |
| Cash & Equivalents | $8.45B | $8.88B | $8.20B | $13.30B | $12.69B |
| Total Debt | $60.50B | $60.53B | $58.64B | $50.48B | $51.97B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $10.64B | $9.11B | $13.43B | $16.18B | $18.27B |
| Capital Expenditures | $2.83B | $2.78B | $3.03B | $2.73B | $2.52B |
| Free Cash Flow | $7.81B | $6.33B | $10.39B | $13.45B | $15.74B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 45.0% | 44.7% | 39.3% | 38.9% | 39.8% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on Equity | 2.3% | 6.1% | 11.2% | 5.9% | 11.1% |
| Return on Assets | 0.7% | 1.8% | 3.5% | 1.9% | 3.5% |
| Debt / Equity | 0.85× | 0.80× | 0.77× | 0.70× | 0.69× |
